Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1573-7276

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma ; volume:30 ; number:7 ; day:15 ; month:5 ; year:2013 ; pages:867-876 ; date:10.2013
Clinical & experimental metastasis ; 30, Heft 7 (15.5.2013), 867-876, 10.2013

Creator: Birkeland, Einar
Busch, Christian
Berge, Elisabet Ognedal
Geisler, Jürgen
Jönsson, Göran
Lillehaug, Johan Richard
Knappskog, Stian
Lønning, Per Eystein

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10585-013-9587-4

URN: urn:nbn:de:101:1-2019062921001224210069

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Birkeland, Einar
Busch, Christian
Berge, Elisabet Ognedal
Geisler, Jürgen
Jönsson, Göran
Lillehaug, Johan Richard
Knappskog, Stian
Lønning, Per Eystein
SpringerLink (Online service)

Other Objects (12)

MEK targeting in N-RAS mutated metastatic melanoma

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

Clinical significance of BRAF mutations in metastatic melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

Hochschulschrift

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy

MEK targeting in N-RAS mutated metastatic melanoma

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

Clinical significance of BRAF mutations in metastatic melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

Hochschulschrift

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy

MEK targeting in N-RAS mutated metastatic melanoma

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

Clinical significance of BRAF mutations in metastatic melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

Hochschulschrift

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

MEK targeting in N-RAS mutated metastatic melanoma

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

Clinical significance of BRAF mutations in metastatic melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy

MEK targeting in N-RAS mutated metastatic melanoma

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

Clinical significance of BRAF mutations in metastatic melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy

MEK targeting in N-RAS mutated metastatic melanoma

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

Clinical significance of BRAF mutations in metastatic melanoma

Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen

Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy

Related objects

Reset password